Vensana Capital Strengthens Team with Key Appointments in Medical Technology Investment

Vensana Capital, a prominent venture capital and growth equity investment firm specializing in medical technology, has announced the appointment of Maria Berkman, MD, as Partner and Ross (Rusty) Segan, MD, as Venture Partner. These appointments underscore Vensana's commitment to deepening its expertise and influence in the medtech sector.

Maria Berkman brings over a decade of experience from Broadview Ventures, where she played a pivotal role in early-stage investments in cardiovascular disease and stroke. Her extensive background in medtech investments, including notable exits such as Apama Medical and CardiAQ, positions her as a valuable asset to Vensana's team. Berkman's dual expertise in medicine and business, evidenced by her MD from UCLA School of Medicine and MBA from UCLA Anderson School of Management, aligns with Vensana's mission to transform healthcare through innovative medical technologies.

Ross (Rusty) Segan joins with over 25 years of experience in the medical device industry, including leadership roles at the FDA, Olympus, and Johnson & Johnson Medical Devices. His clinical and executive experience, combined with his service in the U.S. Army Medical Corp, brings a unique perspective to Vensana's investment strategy. Segan's expertise is expected to drive the firm's efforts in advancing medical technologies that improve patient care globally.

The addition of Berkman and Segan to Vensana's team is a strategic move that enhances the firm's capability to identify and invest in groundbreaking medical technologies. With approximately $1 billion in capital under management, Vensana is well-positioned to support the next generation of medtech companies. These appointments reflect the firm's ongoing commitment to building a team with deep sector expertise to navigate the complexities of the medtech investment landscape.